查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1712507

全球 CRISPR 市场 - 2025-2033

Global CRISPR Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球 CRISPR 市场规模达到 39.3 亿美元，预计到 2033 年将达到 159.2 亿美元，在 2025-2033 年预测期内的复合年增长率为 16.8%。

CRISPR（成簇的规律间隔的短回文重复序列）是一种基因编辑技术，可以对 DNA 进行精确修改，彻底改变了医学、农业和生物技术等领域。透过使用 Cas9 酶，CRISPR 使研究人员能够以惊人的精度添加、删除或改变遗传物质。

其应用包括遗传疾病的基因治疗、癌症研究、作物改良和疾病模型的创建。 CRISPR 试剂盒和耗材为研究人员提供了必要的工具，简化了工作流程并提高了基因编辑实验的可近性。这些试剂盒在学术和临床实验室的应用越来越广泛，促进了创新。此外，CRISPR 文库（针对特定基因的引导 RNA 的集合）支持大规模基因功能研究和药物发现。

市场动态：

驾驶员和约束装置

基因编辑技术的快速进步

基因编辑技术的快速进步极大地推动了 CRISPR 市场的发展，这些技术为肿瘤学、免疫学和罕见疾病等各个领域提供了更精确、更有效率、更具可扩展性的治疗解决方案。这些创新不仅扩大了 CRISPR 的潜在应用，而且还吸引了大型生物製药公司的大量投资，旨在利用其变革潜力。

例如，2023 年 11 月，阿斯特捷利康宣布向临床阶段生物技术公司 Cellectis 投资 2.45 亿美元，作为策略合作的一部分。此次合作旨在利用 Cellectis 专有的基因编辑技术和製造能力来加速下一代治疗方法的开发。此次合作将支持新型细胞和基因疗法的设计，并强调基因编辑的进步如何鼓励主要参与者扩大其在 CRISPR 和更广泛的基因治疗领域的影响力。

此外，随着该技术变得更加精细和普及，它为更多的临床试验、在实验室中的更广泛应用，甚至在个人化医疗中的应用开闢了机会。这种不断的创新不仅突破了 CRISPR 所能实现的界限，而且还推动了市场进一步的投资、合作和成长。

先进 CRISPR 工具和技术的高成本

预计先进 CRISPR 工具和技术的高成本将成为 CRISPR 市场成长的重大障碍。虽然该技术前景广阔，但购买和维护精密设备、试剂和技术人员的费用可能会限制其普及性，特别是对于发展中地区的小型研究机构、新创公司和组织而言。这些资金限制可能会减缓 CRISPR 在学术和商业环境中的采用，阻碍广泛的实验、创新和实施。

此外，成本因素可能会延迟临床应用并限制基于 CRISPR 的治疗的可扩展性，尤其是在预算紧张的医疗保健系统中。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第二章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分类的程式码片段
  • 按应用程式截取的程式码片段
  • 最终用户的程式码片段
  • 按地区分类的片段

第三章：动态

  • 影响因素
    • 驱动程式
      • 基因编辑技术的快速进步。
      • 对个人化和标靶治疗的需求不断增加
    • 限制
      • 先进 CRISPR 工具和技术的高成本
      • 脱靶效应和非预期基因改变的风险
    • 机会
      • 扩大 CRISPR 在药物研发、诊断和农业领域的应用
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • 最新进展与突破
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第五章：CRISPR 市场（依产品类型）

  • CRISPR 试剂盒和耗材
  • CRISPR文库
  • 其他的

第六章：CRISPR 市场（按应用）

  • 药物研发
  • 农业
  • 其他的

第七章：CRISPR 市场（以最终用户划分）

  • 製药公司
  • 生技公司
  • 学术及研究机构
  • 其他的

第八章：CRISPR 市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第九章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第十章：公司简介

  • Thermo Fisher Scientific, Inc.
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 併购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT分析
  • Merck KGaA
  • Agilent Technologies, Inc.
  • GenScript
  • Creative Biogene
  • Bio-Rad Laboratories, Inc.
  • Takara Bio Inc.
  • QIAGEN
  • Eurofins Genomics
  • Synthego

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: BT9502

The global CRISPR market reached US$ 3.93 billion in 2024 and is expected to reach US$ 15.92 billion by 2033, growing at a CAGR of 16.8% during the forecast period 2025-2033.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene-editing technology that allows precise modifications to DNA, revolutionizing fields such as medicine, agriculture, and biotechnology. By using the Cas9 enzyme, CRISPR enables researchers to add, remove, or alter genetic material with remarkable accuracy.

Its applications include gene therapy for genetic disorders, cancer research, crop improvement, and the creation of disease models. CRISPR kits and consumables provide essential tools for researchers, simplifying workflows and enhancing the accessibility of gene-editing experiments. These kits are increasingly used across academic and clinical labs, fostering innovation. Additionally, CRISPR libraries, which are collections of guide RNAs targeting specific genes, support large-scale gene function studies and drug discovery.

Market Dynamics: Drivers & Restraints

Rapid Advancements in Gene Editing Technologies

The CRISPR market is being significantly driven by rapid advancements in gene editing technologies, which are enabling more precise, efficient, and scalable therapeutic solutions across various fields, such as oncology, immunology, and rare diseases. These innovations are not only expanding the potential applications of CRISPR but are also attracting substantial investments from major biopharmaceutical companies aiming to harness its transformative potential.

For instance, in November 2023, AstraZeneca announced a $245 million investment in Cellectis, a clinical-stage biotechnology company, as part of a strategic collaboration. This partnership aims to accelerate the development of next-generation therapeutics by leveraging Cellectis' proprietary gene editing technologies and manufacturing capabilities. The collaboration will support the design of novel cell and gene therapies, highlighting how advancements in gene editing are encouraging major players to expand their presence in the CRISPR and broader gene therapy space.

Additionally, as the technology becomes more refined and accessible, it opens up opportunities for more clinical trials, broader adoption in labs, and even use in personalized medicine. This constant innovation not only pushes the boundaries of what CRISPR can achieve but also fuels further investment, collaboration, and growth within the market.

High Costs Associated with Advanced CRISPR Tools and Technologies

The high costs associated with advanced CRISPR tools and technologies are expected to act as a significant barrier to the growth of the CRISPR market. While the technology holds immense promise, the expense involved in acquiring and maintaining sophisticated equipment, reagents, and skilled personnel can limit its accessibility, especially for smaller research institutions, startups, and organizations in developing regions. These financial constraints may slow down the adoption of CRISPR in both academic and commercial settings, hindering widespread experimentation, innovation, and implementation.

Additionally, the cost factor can delay clinical applications and limit the scalability of CRISPR-based treatments, particularly in healthcare systems with tight budgets.

Segment Analysis

The global CRISPR market is segmented based on product type, application, end-user, and region.

Product Type:

CRISPR kits & consumables in the product type segment are expected to dominate the CRISPR market.

The CRISPR kits and consumables segment is expected to hold a dominant share of the market, largely due to their essential role in gene editing research and growing demand across academic, clinical, and industrial settings. These kits provide researchers with ready-to-use tools that simplify complex CRISPR workflows, making the technology more accessible and efficient.

As more laboratories and institutions adopt CRISPR for various applications, from genetic disease research to agricultural improvements, the need for high-quality, reliable kits and consumables continues to rise. Their recurring use in experiments and routine lab work also ensures steady demand, positioning this segment as a key driver of growth in the CRISPR market.

With the growing need and demand for these kits and consumables are being innovated by the market players are innovating to meet the growing demand. For instance, in March 2024, Carolina Biological Supply Company announced an exclusive partnership with the ChristianaCare Gene Editing Institute to produce and distribute the CRISPR in a Box educational kit. Designed for high school students (grades 9-12) and higher education, this affordable, hands-on lab kit includes printed materials and interactive exercises. It offers students an engaging introduction to CRISPR gene editing.

Geographical Analysis

North America is expected to dominate the global CRISPR market.

North America is anticipated to lead the CRISPR space in the coming years, driven by a strong foundation of advanced biotechnology infrastructure, significant investments in genetic research, and supportive regulatory frameworks. The region has a large number of the world's leading biotech companies, academic institutions, and research organizations that are actively exploring CRISPR-based technologies for applications ranging from disease treatment to agriculture.

The growing number of clinical trials utilizing CRISPR technology is significantly boosting demand and driving the CRISPR market in North America. For instance, in September 2024, KSQ Therapeutics (US) recently received FDA clearance for its IND application for KSQ-004EX, a CRISPR-Cas9 engineered tumor-infiltrating lymphocyte (TIL) therapy.

This approval allows the initiation of a Phase 1/2 clinical trial, sponsored by The University of Texas MD Anderson Cancer Center, to evaluate the therapy's safety and efficacy in patients with advanced solid tumors. The increasing clinical validation of CRISPR-based therapies like KSQ-004EX highlights the growing momentum of gene editing in oncology and its expanding role in shaping the North America CRISPR market.

Competitive Landscape

The global market players in the CRISPR market include Thermo Fisher Scientific, Inc., Merck KGaA, Agilent Technologies, Inc., GenScript, Creative Biogene, Bio-Rad Laboratories, Inc., Takara Bio Inc., QIAGEN, Eurofins Genomics, and Synthego, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global CRISPR market report will provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rapid Advancements in Gene Editing Technologies.
      • 3.1.1.2. Increasing Demand for Personalized and Targeted Therapies
    • 3.1.2. Restraints
      • 3.1.2.1. High costs Associated with Advanced CRISPR Tools and Technologies
      • 3.1.2.2. Risk of off-target Effects and Unintended Genetic Changes
    • 3.1.3. Opportunity
      • 3.1.3.1. Expanding Use of CRISPR in Drug Discovery, Diagnostics, and Agriculture
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Unmet Needs and Gaps
  • 4.9. Recommended Strategies for Market Entry and Expansion
  • 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.11. Pricing Analysis and Price Dynamics

5. CRISPR Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. CRISPR kits & Consumables*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. CRISPR Libraries
  • 5.4. Others

6. CRISPR Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Drug Discovery & Development*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Agriculture
  • 6.4. Others

7. CRISPR Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Pharmaceutical Companies*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Biotechnology Companies
  • 7.4. Academic & Research Institutes
  • 7.5. Others

8. CRISPR Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Thermo Fisher Scientific, Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Merck KGaA
  • 10.3. Agilent Technologies, Inc.
  • 10.4. GenScript
  • 10.5. Creative Biogene
  • 10.6. Bio-Rad Laboratories, Inc.
  • 10.7. Takara Bio Inc.
  • 10.8. QIAGEN
  • 10.9. Eurofins Genomics
  • 10.10. Synthego

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us